Scott Fine has been a Director of the Company since February 2014 and became our Chief Executive Officer on September 14, 2015. From 2004 until 2014, he was a principal at Scarsdale Equities, an investment banking firm located in New York City. Mr. Fine has been involved in investment banking for over 35 years, working on a multitude of debt and equity financings, buy and sell side M&A, strategic advisory work and corporate restructurings. Much of his time has been focused on transactions in the healthcare and consumer products area. Mr. Fine has led global transactions in healthcare, including medical devices, generic pharmaceuticals, and genetics. He also worked with The Tempo Group of Jakarta, Indonesia.
Mr. Fine was Chairman of the Board of The Global Virus Network (GVN), and he also was the lead investment banker on the initial public offering of Green Mountain Coffee Roasters, Inc. and Central European Distribution Corporation (“CEDC”), a multi-billion-dollar alcohol company. Mr. Fine continued his involvement with CEDC serving as a director from 1996 until 2014, during which time he led the CEDC Board in its successful efforts in 2013 to restructure the company through a pre-packaged Chapter 11 process whereby CEDC was acquired by the Russian Standard alcohol group.
Recently, Mr. Fine served as Vice Chairman and Chairman of the Restructuring Committee of Pacific Drilling from 2017 to 2018 where he successfully led the independent directors to a successful reorganization. He also served as sole director of Better Place Inc. from 2013 until 2015. In his role there, Mr. Fine successfully managed the global wind down of the company in a timely and efficient manner which was approved by both the Delaware and Israeli Courts.
Mr. Fine currently serves on the board of directors of Kenon Holdings Ltd. (NYSE: KEN). Mr. Fine also devotes time to several non-profit organizations, including through his service on the Board of Trustees for the IWM American Air Museum in Britain. Mr. Fine has been a guest lecturer at Ohio State University’s Moritz School of Law and Fordham University Law School.
What is N. Scott Fine's net worth?
The estimated net worth of N. Scott Fine is at least $314,992.14 as of April 20th, 2023. Mr. Fine owns 444,402 shares of Cyclo Therapeutics stock worth more than $314,992 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Fine may own. Additionally, Mr. Fine receives an annual salary of $569,920.00 as CEO at Cyclo Therapeutics. Learn More about N. Scott Fine's net worth.
How old is N. Scott Fine?
What is N. Scott Fine's salary?
How do I contact N. Scott Fine?
Has N. Scott Fine been buying or selling shares of Cyclo Therapeutics?
N. Scott Fine has not been actively trading shares of Cyclo Therapeutics during the last quarter. Most recently, on Thursday, April 20th, N Scott Fine bought 299,402 shares of Cyclo Therapeutics stock. The stock was acquired at an average cost of $0.71 per share, with a total value of $212,575.42. Following the completion of the transaction, the chief executive officer now directly owns 444,402 shares of the company's stock, valued at $315,525.42. Learn More on N. Scott Fine's trading history.
Who are Cyclo Therapeutics' active insiders?
